Mathematica Policy Research, Inc., Washington, DC 20024, USA.
Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1048-52. doi: 10.1002/pds.1819.
To describe utilization patterns for anti-diabetes medications among a cohort of diabetes patients in the Military Health System (MHS) before and after warnings about rosiglitazone issued in May 2007.
We used segmented regression analysis to compare changes in the level and trend of rosiglitazone utilization and use of other anti-diabetes therapies in the period prior to the drug warnings (between April 2006 and May 2007) and the period after the warnings were issued (between October 2007 and May 2008).
The level and trend of rosiglitazone use changed after the highly publicized warnings. The number of prescriptions filled fell by almost 7000 after the warning (p < 0.001). The number of prescriptions filled for pioglitazone, sulfonylureas, and other diabetes drugs increased significantly after the warnings (p < 0.05 in all models). Overall, the level and trend of filled prescriptions per month for all anti-diabetic drugs did not significantly change after the warnings.
Utilization patterns changed in response to warnings about rosiglitazone. While overall utilization of anti-diabetic drugs did not change, further study is needed to determine the associated health outcomes.
描述 2007 年 5 月发布罗格列酮警告前后，军事医疗系统（MHS）中糖尿病患者使用抗糖尿病药物的情况。
我们使用分段回归分析比较了在药物警告发布之前（2006 年 4 月至 2007 年 5 月）和之后（2007 年 10 月至 2008 年 5 月）期间，罗格列酮的使用水平和趋势以及其他抗糖尿病疗法的使用变化。
在发布高度宣传的警告后，罗格列酮的使用水平和趋势发生了变化。警告后，开出的处方数量下降了近 7000 张（p<0.001）。警告后，吡格列酮、磺酰脲类药物和其他糖尿病药物的处方数量显著增加（所有模型中 p<0.05）。总体而言，警告后所有抗糖尿病药物每月开出的处方数量水平和趋势均无显著变化。
对罗格列酮的警告做出了反应，利用模式发生了变化。虽然抗糖尿病药物的总体利用没有改变，但需要进一步研究以确定相关的健康结果。
